Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial

• DOI: 10.1007/s41030-020-00136-3
• Publication Date: 2020-11-17T13:02:45Z
• Authors: David M. G. Halpin; Gerard J. Criner; Mark T. Dransfield; MeiLan K. Han; Benjamin Hartley; Catherine Harvey; C. Elaine Jones; Motokazu Kato; Peter Lange; Sally Lettis; David A. Lomas; Fernando J. Martinez; Neil Martin; Dave Singh; Robert Wise; Jinping Zheng; David A. Lipson
• Keywords: INDACATEROL/GLYCOPYRRONIUM; Asia; SUBGROUP ANALYSIS; PNEUMONIA RISK; Pneumonia; EFFICACY; Chronic obstructive; 3. Good health; EXACERBATIONS; 03 medical and health sciences; VILANTEROL; 0302 clinical medicine; SAFETY; INHALED FLUTICASONE FUROATE; COPD PATIENTS; Drug therapy; Mortality; Pulmonary disease; TIOTROPIUM; Original Research

In the IMPACT trial, single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation rates versus FF/VI or UMEC/VI dual in patients with chronic obstructive pulmonary disease (COPD); however, pneumonia incidence was higher FF-containing arms. As COPD is a growing problem Asia, we compared efficacy and safety of FF/UMEC/VI Asia non-Asia regions.